, Tracking Stock Market Picks
Enter Symbol:
Rating: REGN
Sell $565

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) downgraded to Sell with price target $565 by UBS

Wednesday,  Aug 5, 2015  11:25 AM ET by Lynn Gilbert

UBS downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Sell with price target $565. Previously, UBS rated Regeneron Pharmaceuticals,
Inc. (NASDAQ: REGN) to Neutral with price target $412 on 02/11/2015, when the stock price was valued at $400.50. Since then, Regeneron Pharmaceuticals, Inc.'s stock price has gained 48% as of 08/05/2015's recent price of $592.80.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy